Endocrine Abstracts

Case history: A patient with malignant melanoma with multiple cerebral metastases and a left adrenal metastasis was treated with CRT (30Gy, 10 fractions). This was followed by 12 cycles of Nivolumab, after which the left adrenal lesion was managed with cyberknife (30Gy, three fractions) and Nivolumab was continued thereafter. The patient developed worsening deafness, became unsteady on his feet and complained of feeling generally unwell. At this time an MRI brain was performed...

Background: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, demonstrating durable responses, but can result in immune-related adverse events (irAEs). Endocrinopathies are amongst the more common adverse events, and thyroid dysfunction and hypophysitis being the most frequent; the latter of these has been positively correlated with oncological outcome. This study compared overall survival (OS), progression-free survival (PFS) and disease c...

Background: Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, demonstrating durable responses, but can result in immune-related adverse events (irAEs). Endocrinopathies are amongst the more common adverse events, and thyroid dysfunction and hypophysitis being the most frequent; the latter of these has been positively correlated with oncological outcome. This study compared overall survival (OS), progression-free survival (PFS) and disease c...

: Recent Phase 3 studies have demonstrated the clinical utility of immunotherapy with inhibitors of PD1 in cancers, including melanoma and non-small cell lung cancer. Autoimmune side effects are common. Both hypothyroidism and hyperthyroidism have been observed in up to 16% of patients. We report for the first time the endocrine evaluation of patients with anti-PD1 induced thyroid dysfunction.Methods: All patients treated in published trials of anti-PD1 ...

Background: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibitor that improves survival in advanced melanoma. However, ipilimumab induces immune-related adverse events including hypophysitis and hypopituitarism. We describe one of the largest single centre series of ipilimumab induced hypophysitis.Methods: We retrospectively analysed all patients (n=301) treated with ipilimumab either as a monotherapy or in combination with nivolu...